drugset / Trial / NCT07343947

Melatonin Supplementation in Ovarian Response

NCT07343947

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Melatonin is a potent antioxidant, has been proposed to improve ovarian response and oocyte quality in assisted reproductive technologies (ART). This study evaluated the effects of melatonin supplementation on follicular fluid melatonin levels, hormonal profiles, and reproductive outcomes in women undergoing in vitro fertilization (IVF). Follicular fluid and serum melatonin levels, oocyte quality, embryo development, and pregnancy rates were assessed.

Timeline

Start
2022-01-31
Primary completion
2023-12-01
Completion
2023-12-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 5 mg

Indications